RMD Stock Analysis: ResMed | NYSE
Medical Instruments & Supplies | NYSE, USA | Market Cap: 30.785m USD | 12M Return: -16.3% | US7611521078 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 239M
EPS Trend: 99.4%
Qual. Beats: 1
Rev. Trend: 100.0%
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
ResMed Inc. (NYSE: RMD) is a U.S.-based digital health and medical device company operating in two main segments: Sleep and Breathing Health, and Residential Care Software. The company manufactures diagnostic tools for sleep apnea, including portable recorders like ApneaLink Air and the cloud-connected NightOwl device, and provides connected therapy solutions such as AirView for remote monitoring and the myAir patient engagement app. Through its Residential Care Software segment, ResMed offers SaaS-based platforms-including Brightree, HEALTHCAREfirst, MatrixCare, and MEDIFOX DAN-serving home medical equipment, home health, hospice, skilled nursing, and senior living providers.
Founded in 1989 and headquartered in San Diego, California, ResMed is classified as a large-cap stock in the Health Care Equipment sub-industry, with operations spanning the U.S. and international markets. The company sits at the intersection of medical device manufacturing and healthcare software, leveraging connectivity and cloud platforms to support chronic disease management, particularly sleep-disordered breathing and post-acute care.
- GLP-1 weight loss drugs threaten sleep apnea device demand
- Philips recall recovery intensifies competition in CPAP market
- Residential Care Software segment drives recurring revenue growth
| Net Income: 1.52b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.32 > 0.02 and ΔFCF/TA 11.94 > 1.0 |
| NWC/Revenue: 51.82% < 20% (prev 48.32%; Δ 3.50% < -1%) |
| CFO/TA 0.35 > 3% & CFO 3.16b > Net Income 1.52b |
| Net Debt (-476.8m) to EBITDA (2.15b): -0.22 < 3 |
| Current Ratio: 3.10 > 1.5 & < 3 |
| Outstanding Shares: last quarter (145.0m) vs 12m ago -1.40% < -2% |
| Gross Margin: 61.16% > 18% (prev 59.36%; Δ 1.80% > 0.5%) |
| Asset Turnover: 65.97% > 50% (prev 62.96%; Δ 3.01% > 0%) |
| Interest Coverage Ratio: 39.04 > 6 (EBIT TTM 1.95b / Interest Expense TTM 49.9m) |
| A: 0.33 (Total Current Assets 4.32b - Total Current Liabilities 1.40b) / Total Assets 8.97b |
| B: 0.81 (Retained Earnings 7.26b / Total Assets 8.97b) |
| C: 0.23 (EBIT TTM 1.95b / Avg Total Assets 8.57b) |
| D: 2.77 (Book Value of Equity 6.59b / Total Liabilities 2.38b) |
| Altman-Z'' = 9.21 = AAA |
| DSRI: 0.95 (Receivables 1.04b/990.7m, Revenue 5.65b/5.15b) |
| GMI: 0.97 (GM 59.36% / 61.16%) |
| AQI: 0.90 (AQ_t 0.44 / AQ_t-1 0.48) |
| SGI: 1.10 (Revenue 5.65b / 5.15b) |
| TATA: -0.18 (NI 1.52b - CFO 3.16b) / TA 8.97b) |
| Beneish M = -3.10 (Cap -4..+1) = AA |
As of October 12, 2026, the stock is trading at USD 230.05 with a total of 979,651 shares traded. Over the past week, the price has changed by +5.10%, over one month by +4.59%, over three months by +10.68% and over the past year by -16.34%.
Current recommended Stop Loss: 220.70 (which is 4.1% or 1.7 ATR below the current price).
ResMed has received a consensus analysts rating of 3.70. Therefore, it is recommended to hold RMD.
- StrongBuy: 7
- Buy: 2
- Hold: 10
- Sell: 0
- StrongSell: 1
| Analysts Target Price | 250.2 | 8.8% |
P/E Trailing = 21.0067
P/E Forward = 18.5185
P/S = 5.4453
P/B = 4.8695
P/EG = 1.2899
Revenue TTM = 5.65b USD
EBIT TTM = 1.95b USD
EBITDA TTM = 2.15b USD
Long Term Debt = 399.4m USD (from longTermDebt, last quarter)
Short Term Debt = 289.1m USD (from shortTermDebt, last quarter)
Debt = 992.5m USD (from shortLongTermDebtTotal, last quarter) + Leases 166.6m
Net Debt = -476.8m USD (calculated: Debt 992.5m - CCE 1.47b)
Enterprise Value = 30.3b USD (30.8b + Debt 992.5m - CCE 1.47b)
Interest Coverage Ratio = 39.04 (Ebit TTM 1.95b / Interest Expense TTM 49.9m)
EV/FCF = 10.49x (Enterprise Value 30.3b / FCF TTM 2.89b)
FCF Yield = 9.53% (FCF TTM 2.89b / Enterprise Value 30.3b)
FCF Margin = 51.11% (FCF TTM 2.89b / Revenue TTM 5.65b)
Net Margin = 26.94% (Net Income TTM 1.52b / Revenue TTM 5.65b)
Gross Margin = 61.16% ((Revenue TTM 5.65b - Cost of Revenue TTM 2.20b) / Revenue TTM)
Gross Margin QoQ = 58.84% (prev 62.25%)
Tobins Q-Ratio = 3.38 (Enterprise Value 30.3b / Total Assets 8.97b)
Interest Expense / Debt = 5.03% (Interest Expense 49.9m / Debt 992.5m)
Taxrate = 20.64% (396.1m / 1.92b)
NOPAT = 1.55b (EBIT 1.95b * (1 - 20.64%))
Current Ratio = 3.10 (Total Current Assets 4.32b / Total Current Liabilities 1.40b)
Debt / Equity = 0.15 (Debt 992.5m / totalStockholderEquity, last quarter 6.59b)
Debt / EBITDA = -0.22 (Net Debt -476.8m / EBITDA 2.15b)
Debt / FCF = -0.16 (Net Debt -476.8m / FCF TTM 2.89b)
Total Stockholder Equity = 6.38b (last 4 quarters mean from totalStockholderEquity)
RoA = 17.77% (Net Income 1.52b / Total Assets 8.97b)
RoE = 23.88% (Net Income TTM 1.52b / Total Stockholder Equity 6.38b)
RoCE = 28.74% (EBIT 1.95b / Capital Employed (Equity 6.38b + L.T.Debt 399.4m))
RoIC = 20.41% (NOPAT 1.55b / Invested Capital 7.58b)
WACC = 7.36% (E(30.8b)/V(31.8b) * Re(7.47%) + D(992.5m)/V(31.8b) * Rd(5.03%) * (1-Tc(0.21)))
Discount Rate = 7.47% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -72.55 | Cagr: -0.75%
[DCF] Terminal Value 77.97% ; FCFF base≈2.40b ; Y1≈2.75b ; Y5≈4.04b
[DCF] Fair Price = 436.1 (EV 60.9b - Net Debt -476.8m = Equity 61.3b / Shares 140.6m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 99.39 | EPS CAGR: 21.79% | SUE: 0.97 | # QB: 1
Revenue Correlation: 99.96 | Revenue CAGR: 9.71% | SUE: 0.20 | # QB: 0
EPS current Quarter (2026-09-30): EPS=2.67 | Chg30d=-0.73% | Revisions=-58% | Analysts=13
EPS next Quarter (2026-12-31): EPS=3.03 | Chg30d=-0.18% | Revisions=-25% | Analysts=13
EPS current Year (2027-06-30): EPS=12.09 | Chg30d=+0.00% | Revisions=+47% | GrowthEPS=+8.2% | GrowthRev=+2.7%
EPS next Year (2028-06-30): EPS=13.23 | Chg30d=+0.10% | Revisions=+29% | GrowthEPS=+9.5% | GrowthRev=+6.3%
[Analyst] Revisions Ratio: +6% (up=15, down=13)